Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome p450 3a4 and p-glycoprotein

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3168-3176

  Horita, Yasuhiro ^a   Doi, Norio ^a  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYTOCHROME P450 3A4; EFAVIRENZ; ENVIOMYCIN; ERYTHROMYCIN; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; LINEZOLID; LOPERAMIDE; MACROLIDE; MEROPENEM; MULTIDRUG RESISTANCE PROTEIN; NEVIRAPINE; PROTIONAMIDE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; RITONAVIR; ROXITHROMYCIN; SPIRONOLACTONE; THIOACETAZONE; THIOAMIDE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450 3A INHIBITOR;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; EX VIVO STUDY; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; MDCK CELL LINE; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; WORLD HEALTH ORGANIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DOG;

ANIMALS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CELL LINE; CYTOCHROME P-450 CYP3A INHIBITORS; DOGS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; P-GLYCOPROTEIN;

EID: 84901285598     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02278-13     Document Type: Article

References (67)

1. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12: 388-404. http://dx.doi.org/10.1038/nrd4001.
2. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/ 10665/75938/1/9789241564502-eng.pdf.
3. Mahajan R. 2013. Bedaquiline: first FDA-Approved tuberculosis drug in 40 years. Int. J. Appl. Basic Med. Res. 3:1-2. http://dx.doi.org/10.4103/2229-516X. 112228.
4. Coyne KM, Pozniak AL, Lamorde M, Boffito M. 2009. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 23:437-446. http://dx.doi.org/10.1097/QAD. 0b013e328326ca50.
5. O'Connor R, O'Sullivan JF, O'Kennedy R. 1995. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab. Rev. 27:591-614. http://dx.doi.org/10.3109/03602539508994208.
6. Qian L, Ortiz de Montellano PR. 2006. Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. Chem. Res. Toxicol. 19:443-449. http://dx.doi.org/10.1021/ tx050328b.
7. Bolhuis MS, van Altena R, Uges DRA, van der Werf TS, Kosterink JGW, Alffenaar JWC. 2010. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob. Agents Chemother. 54:5418-5419. http://dx.doi.org/ 10.1128/AAC.00757-10.
8. Stalker DJ, Jungbluth GL. 2003. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet. 42:1129-1140. http://dx.doi.org/10.2165/00003088-200342130-00004.
9. Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, Climent C, Brunet M, Cuesta M, Mensa J, Soriano A. 2012. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand. J. Infect. Dis. 44:548-550. http://dx.doi.org/10.3109/00365548.2012.663931.
10. Gebhart BC, Barker BC, Markewitz BA. 2007. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 27:476-479. http://dx.doi.org/10.1592/phco.27.3.476.
11. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J. 1999. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 27:895-901.
12. von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, Harmatz JS, Shader RI. 2001. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J. Clin. Pharmacol. 41:85-91. http://dx.doi.org/10.1177/00912700122009728.
13. East African/British Medical Research Council Thiacetazone/ Diphenylthiourea Investigation. 1960. Comparative trial of isoniazid in combination with thiacetazone or a substituted diphenylthiourea (SU1906) or PAS in the treatment of acute pulmonary tuberculosis in east Africans: a co-operative investigation in east African hospitals and laboratories with the collaboration of the British Medical Research Council. Tubercle 41:399-423. http://dx.doi.org/10.1016/S0041-3879(60)80048-7.
14. Sahota T, Della Pasqua O. 2012. Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis. Antimicrob. Agents Chemother. 56:5442-5449. http://dx.doi.org/10.1128/AAC.05988-11.
15. Donald P, Maher D, Maritz S, Qazi S. 2006. Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2006/who-htm-tb-2006.365-eng.pdf.
16. Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z, Tuberculosis Trials Consortium. 2005. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin. Infect. Dis. 41:1343-1349. http://dx.doi.org/10.1086/496980.
17. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2012. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations: draft guidance. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm292362.pdf.
18. European Medicines Agency. 2010. Guideline on the investigation of drug interactions. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 05/WC500090112.pdf.
19. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63. http://dx.doi.org/10.1016/0022-1759(83)90303-4.
20. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. 1986. An improved colorimetric assay for interleukin 2. J. Immunol. Methods 93: 157-165. http://dx.doi.org/10.1016/0022-1759(86)90183-3.
21. Global Alliance for Drug Development TB. 2008. Handbook of antituberculosis agents. Introduction. Tuberculosis (Edinb.) 88:85-86. http://dx.doi.org/10.1016/S1472-9792(08)70002-7.
22. Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I. 2006. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab. Dispos. 34:793-799. http://dx.doi.org/10.1124/dmd.105.007559.
23. Desta Z, Soukhova NV, Flockhart DA. 2001. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. 45:382-392. http://dx.doi.org/10.1128/AAC.45.2. 382-392.2001.
24. Wen X, Wang JS, Neuvonen PJ, Backman JT. 2002. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 57:799-804. http://dx.doi.org/10.1007/s00228-001-0396-3.
25. McLellan RA, Drobitch RK, Monshouwer M, Renton KW. 1996. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab. Dispos. 24:1134-1138.
26. Peters JH, Hamme KJ, Gordon GR. 1982. Determination of clofazimine in plasma by high-performance liquid chromatography. J. Chromatogr. B 229:503-508. http://dx.doi.org/10.1016/S0378-4347(00)84299-1.
27. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, Cheng LK. 1997. Primary human hepatocytes as a tool for the evaluation of structure-Activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 107:17-30. http://dx.doi.org/10.1016/S0009-2797 (97)00071-9.
28. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Bäckman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A. 1998. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U. S. A. 95:12208-12213. http://dx.doi.org/10.1073/pnas.95.21.12208.
29. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H. 2007. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320:72-80. http://dx.doi.org/10.1124/jpet. 106.112136.
30. Lambert CB, Spire C, Claude N, Guillouzo A. 2009. Dose-And timedependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol. Appl. Pharmacol. 234:345-360. http://dx.doi.org/10.1016/j.taap. 2008.11.008.
31. Kwara A, Ramachandran G, Swaminathan S. 2010. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin. Drug Metab. Toxicol. 6:55-68. http://dx.doi.org/10.1517/174 25250903393752.
32. Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, Guguen-Guillouzo C, Guillouzo A. 2010. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab. Dispos. 38:516-525. http://dx.doi.org/10.1124/dmd.109.030197.
33. Wilkening S, Stahl F, Bader A. 2003. Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metab. Dispos. 31:1035-1042. http://dx.doi.org/10.1124/dmd.31. 8.1035.
34. Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA. 2012. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol. Toxicol. 28:69-87. http://dx.doi.org/10.1007/s10565-011-9208-4.
35. Nakamura K, Kato N, Aizawa K, Mizutani R, Yamauchi J, Tanoue A. 2011. Expression of albumin and cytochrome P450 enzymes in HepG2 cells cultured with a nanotechnology-based culture plate with microfabricated scaffold. J. Toxicol. Sci. 36:625-633. http://dx.doi.org/10.2131/jts.36.625.
36. O'Connor JE, Martínez A, Castell JV, Gómez-Lechón MJ. 2005. Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research. Cytometry A 63:48-58. http://dx.doi.org/10.1002/cyto.a.20095.
37. Kenny JR, Chen L, McGinnity DF, Grime K, Shakesheff KM, Thomson B, Riley R. 2008. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRTPCR) and substrate cassette methodologies. Xenobiotica 38:1500-1517. http://dx.doi.org/10.1080/ 00498250802495846.
38. McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, Riley RJ. 2009. Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab. Dispos. 37:1259-1268. http://dx.doi.org/10.1124/dmd.109.026526.
39. Venkatesan K, Bharadwaj VP, Ramu G, Desikan KV. 1980. Study on drug interactions. Lepr. India 52:229-235.
40. Venkatesan K, Deo N, Gupta UD. 2007. Tissue distribution and deposition of clofazimine in mice following oral administration with or without isoniazid. Arzneimittelforschung. 57:472-474. http://dx.doi.org/10.1055/s-0031-1296634.
41. Mehta J, Gandhi IS, Sane SB, Wamburkar MN. 1985. Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Indian J. Lepr. 57:297-310.
42. Mehta J, Gandhi IS, Sane SB, Wamburkar MN. 1986. Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Lepr. Rev. 57(Suppl 3):67-76.
43. Van Rensburg CE, Anderson R, O'Sullivan JF. 1997. Riminophenazine compounds: pharmacology and anti-neoplastic potential. Crit. Rev. Oncol. Hematol. 25:55-67. http://dx.doi.org/10.1016/S1040-8428(96)00229-6.
44. Dooley KE, Kim PS, Williams SD, Hafner R. 2012. TB and HIV therapeutics: pharmacology research priorities. AIDS Res. Treat 2012:874083. http://dx.doi.org/10.1155/2012/874083.
45. Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, Ma X. 2014. Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab. Dispos. http://dx.doi.org/10.1124/dmd.113.056119.
46. Yang T, Pauli E, Upton EA, Wargin W, Shadiack MA, Ma Z. 2012. In vitro profiling of the absorption, distribution, metabolism, and excretion properties of the nitroimidazole TBA-354, abstr F-839. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 9 to 12 September 2012.
47. Fahmi OA, Kish M, Boldt S, Obach RS. 2010. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-Activated induction of drug-metabolizing enzymes. Drug Metab. Dispos. 38:1605-1611. http://dx.doi.org/10.1124/dmd.110.033126.
48. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. 2001. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab. Dispos. 29:100-102.
49. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. 2002. Effect of 17-Alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther. 300:549-558. http://dx.doi.org/10.1124/jpet.300.2.549.
50. Lamson M, MacGregor T, Riska P, Erickson D, Maxfield P, Rowland L, Gigliotti M, Robinson P, Azzam S, Keirns J. 1999. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin. Pharmacol. Ther. 65:137.
51. Bolhuis MS, van Altena R, van Soolingen D, de Lange WC, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW. 2013. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur. Respir. J. 42:1614-1621. http://dx.doi.org/10.1183/09031936.00001913.
52. Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, Damle B. 2011. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J. Clin. Pharmacol. 51:229-236. http://dx.doi.org/10.1177/0091270010366445.
53. Egle H, Trittler R, Kümmerer K, Lemmen SW. 2005. Linezolid and rifampin: drug interaction contrary to expectations? Clin. Pharmacol. Ther. 77:451-453. http://dx.doi.org/10.1016/j.clpt.2005.01.020.
54. Ohmori S, Horie T, Hayashi S, Kitada M. 1994. Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology 48:137-142. http://dx.doi.org/10.1159/000139172.
55. Van Rensburg CE, Anderson R, Myer MS, Jooné GK, O'Sullivan JF. 1994. The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line. Cancer Lett. 85:59-63. http://dx.doi.org/10.1016/0304-3835(94)90239-9.
56. Myer MS, Van Rensburg CE. 1996. Chemosensitizing interactions of clofazimine and B669 with human K562 erythroleukaemia cells with varying levels of expression of P-glycoprotein. Cancer Lett. 99:73-78. http://dx.doi.org/10. 1016/0304-3835(95)04039-0.
57. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. 2013. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob. Agents Chemother. 57:6366-6369. http://dx.doi.org/10.1128/AAC.01124-13.
58. Choi MK, Jin QR, Choi YL, Ahn SH, Bae MA, Song IS. 2011. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. Biopharm. Drug Dispos. 32:175-184. http://dx.doi.org/10.1002/bdd.749.
59. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35: 1853-1859. http://dx.doi.org/10.1124/dmd.107.016089.
60. Kanebratt KP, Andersson TB. 2008. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 36:1444-1452. http://dx.doi.org/10.1124/dmd.107.020016.
61. Kakuni M, Yamasaki C, Tachibana A, Yoshizane Y, Ishida Y, Tateno C. 2014. Chimeric mice with humanized livers: a unique tool for in vivo and in vitro enzyme induction studies. Int. J. Mol. Sci. 15:58-74. http://dx.doi.org/10.3390/ ijms15010058.
62. Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez FJ. 2007. The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab. Dispos. 35:194-200. http://dx.doi.org/10.1124/dmd.106.012831.
63. Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma X. 2013. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat. Med. 19:418-420. http://dx.doi.org/10. 1038/nm.3104.
64. Hasegawa M, Tahara H, Inoue R, Kakuni M, Tateno C, Ushiki J. 2012. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver. Drug Metab. Dispos. 40:474-480. http://dx.doi.org/10. 1124/dmd.111.042754.
65. Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE. 2001. Pharmacokinetics of para-Aminosalicylic acid granules under four dosing conditions. Ann. Pharmacother. 35:1332-1338.
66. Dietze R, Teixeira L, Rocha LM, Palaci M, Johnson JL, Wells C, Rose L, Eisenach K, Ellner JJ. 2001. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 45:1972-1976. http://dx.doi.org/10.1128/AAC.45.7.1972-1976.2001.
67. Peloquin CA, Nitta AT, Berning SE, Iseman MD, James GT. 1996. Pharmacokinetic evaluation of thiacetazone. Pharmacotherapy 16:735-741. http://dx.doi.org/10.1002/j.1875-9114.1996.tb02990.x.